OK Biotech CoTPE:4155 60 Net Margin % is 15.86% as of Dec. 2025, which is 87% above its 10-year median of 8.47. GuruFocus rates TPE:4155 with a GF Score™ of 60/100 and a GF Value™ of NT$27.28 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 817 Medical Devices & Instruments companies, OK Biotech Co ranks better than 59.36% on this metric.
Net margin is calculated as Net Income divided by its Revenue. OK Biotech Co's Net Income for the
three
months ended in Dec. 2025 was NT$54 Mil. OK Biotech Co's Revenue for the
three
months ended in Dec. 2025 was NT$338 Mil. Therefore, OK Biotech Co's net margin for the quarter that ended in Dec. 2025 was 15.86%.
The historical rank and industry rank for OK Biotech Co's Net Margin % or its related term are showing as below:
TPE:4155'
s Net Margin % Range Over the Past 10 Years
Min: 0.25 Med: 8.47 Max: 14.4
Current: 5.3
TPE:4155's Net Margin % is ranked better than 59.36% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.07
vs TPE:4155: 5.30
OK Biotech Co (TPE:4155) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
OK Biotech Co Net Margin % Related Terms
OK Biotech Co Net Margin % Historical Data
* Premium members only.
The historical data trend for OK Biotech Co's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4155 vs ABT, SYK, MDT: Net Margin % Comparison
For the Medical Devices subindustry, OK Biotech Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OK Biotech Co Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, OK Biotech Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where OK Biotech Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OK Biotech Co (TPE:4155) has a Net Margin % of 15.86% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on OK Biotech Co and its competitors. This is 87% above median its historical median of 8.47. Over the past decade, OK Biotech Co's Net Margin % has ranged from 0.25 to 14.40. According to the industry distribution chart, OK Biotech Co ranks #332 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 40.6%.
Is OK Biotech Co's Net Margin % too high?
OK Biotech Co's current Net Margin % of 15.86% is 87% above median its 10-year median of 8.47. Over the past 10 years, this metric has ranged from a low of 0.25 to a high of 14.40. The Medical Devices & Instruments industry median Net Margin % is 2.07. OK Biotech Co's value of 15.86% is 666.2% above this industry median. Based on the distribution chart, OK Biotech Co ranks #332 out of 817 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, OK Biotech Co has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does OK Biotech Co's Net Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, OK Biotech Co ranks #332 out of 817 companies for Net Margin %. This puts OK Biotech Co in the upper half of its industry. The industry median Net Margin % is 2.07. OK Biotech Co's value of 15.86% is 666.2% above this benchmark. Historically, OK Biotech Co's own Net Margin % has ranged from 0.25 to 14.40 over the past decade. While the company's 10-year median is 8.47 vs. the industry median of 2.07, OK Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.07, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OK Biotech Co's current Net Margin % of 15.86% is 666.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on OK Biotech Co and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OK Biotech Co's current Net Margin % is 15.86%, which is 87% above median its own 10-year median of 8.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OK Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, OK Biotech Co (TPE:4155) is currently considered Possible Value Trap. The stock's GF Value™ is NT$27.28, compared to a current price of NT$15.00 — trading 45% below its estimated fair value. The current Net Margin % is 15.86%, which is 87% above median its 10-year median of 8.47 and 666.2% above the Medical Devices & Instruments industry median of 2.07. OK Biotech Co's overall GF Score™ is 60/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For OK Biotech Co (TPE:4155), the current Net Margin % is 15.86% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OK Biotech Co (TPE:4155) Overvalued in 2026?
Based on GuruFocus' analysis, OK Biotech Co stock appears to be undervalued.
The current stock price of NT$15.00 is trading 45% below its estimated GF Value™ of NT$27.28.
GuruFocus considers OK Biotech Co to be Possible Value Trap.
Key valuation signals for TPE:4155:
Net Margin %: 15.86% (87% above median its 10-year median of 8.47)
GF Value™: NT$27.28 vs. price of NT$15.00 (45% below fair value)
Industry Position: 666.2% above the Medical Devices & Instruments median (#332 of 817)
No single metric tells the full story. See the TPE:4155 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OK Biotech Co Ltd is mainly engaged in the manufacturing, wholesale, and retail of electronic materials and medical equipment. Its product portfolio comprises blood glucose monitoring systems, OTC hearing aids, multi-frequency therapy devices, and others. Geographically, the company generates the majority of its revenue from America, and the rest from Asia (excluding Taiwan), Africa, Europe, and Taiwan.
60GF Score
Get the complete analysis for TPE:4155
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4155 has been successfully added to your 
